STT-5058 / argenx, Staten Biotech  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
STT-5058 / Staten Biotech
NCT04419688: A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Terminated
1
93
Europe
STT-5058, Placebo
Staten Biotechnology BV
Hypertriglyceridemia
12/22
12/22

Download Options